Johnson & Johnson (JNJ) Buy, Sell or Hold

Home

Daily Stock Opinions and Ratings

Johnson & Johnson (JNJ)

232.16

-0.61 (0.26%)

as of Jun 8, 2026, 8:00:00 pm Market Open.

698 watching

Investor Insights

Jun 8, 2026, 12:00 am

This summary was created by AI, based on 12 opinions in the last 12 months.

Johnson & Johnson (JNJ) has been experiencing a transformative period, especially following the spinoff of its orthopedics division, allowing it to focus more on pharmaceuticals and medical devices. Experts have highlighted the company's strong drug pipeline and robust performance in its core pharmaceutical business, which has led to a significant increase in stock value this year. Despite some concerns regarding ongoing talcum powder litigation and its past underwhelming performance, many analysts believe the legal risks are diminishing. The stock is seen as a better long-term hold, with potential dividend growth, especially amidst a broader economic context affecting consumer products. Overall, JNJ is viewed as an attractive investment, particularly when bought on weakness, with the valuation appearing favorable due to its premium position in the healthcare sector.

Consensus

Buy

Valuation

Fair Value

Similar

PAST TOP PICK

(A Top Pick Dec 22/08. Up 12.92%.)

Wealthica Track your Stocks in your Watch List

BUY

Great holding. Gives you a piece of pharma, consumer goods and medical devices. 3.2% dividend. Trades at a reasonable multiple.

DON'T BUY

Great leadership name. Trading at around 12X forward earnings. Healthcare stocks tend not to do well when the market starts moving up. Quarterly estimates are being revised downwards. 3.25% dividend. Would prefer Pfizer (PFE-N).

PAST TOP PICK

(A Top Pick Oct 23/08. No change.) Still likes. Not just a pharmaceutical company but also consumer and medical devices businesses. Great balance sheet. 3%+ dividend. Historically has done a great job of growing its equity 10%-15%. Great core holding.

WAIT

(Market Call Minute.) Probably not a Buy for the next 3 or 4 months but longer-term it would be a buy.

PAST TOP PICK

(A Top Pick Sept 3/08. Down 15%.) Made a V base. 200-day moving average around $55. Would love to buy if it broke into new highs. Anything above $62-$63 would be confirmation of the beginning of a new leg.

BUY

Household brand company with a tremendous franchise. Solid balance sheet and solid dividend. No matter what happens, it is not going to hurt you too badly. Be aware that on dividends outside Canada, you pay a lot more tax.

BUY ON WEAKNESS

Probably one of the best US pharmaceuticals. Also have consumer products. Steady earnings and dividend growth for over 20 years. The only risk is the currency effect by investing in a US company. Would like it at $57-$58.

Wealthica Track your Stocks in your Watch List

TOP PICK

Healthcare space so is reasonably defensive. Well diversified including consumer products, prescription drugs and medical devices. Fantastic balance sheet management. About a 4% yield. History of increasing dividends.

PAST TOP PICK

(A Top Pick July 3/09. Up 7.31%.) Likes the diverse products in their pharmaceutical and medical devices as well as their consumer products area. Still a Buy.

TOP PICK

Sector most out of favour right now is healthcare. This is one of the most respected companies in the world with a very strong balance sheet. A leader in all its businesses. Wonderful consumer business. Very cheap with a 14 multiple.

BUY

Consumer discretionary and pharmaceuticals. A premier in its class. It does well when the US$ depreciates because of all their sales outside of the country. Good defensive play. Very good free cash flow. 3.2% yield.

PAST TOP PICK

(A Top Pick Aug 5/08. Down 12.21%.)

BUY

Large-cap fully integrated global pharmaceutical. Earnings beat expectations. Competition from generics but their pipeline going forward looks extremely robust.

BUY

Consumer staples, pharmaceuticals, utilities and telecoms have been have been enormous under performers during this rally. Rock solid. Pretty decent dividend.

Showing 466 to 480 of 626 entries

Most Recent Experts

Jim Cramer - Mad Money

CNBC

Larry Berman CFA, CMT, CTA

ETF Capital Management Inc.

Mike Vinokur, CFA, CMT, and CFP

Propellus Wealth Partners/iA Private Wealth

Brian Madden

First Avenue Investment Counsel

The Panic-Proof Portfolio (Stockchase Research)

Stockchase Premium

Stockchase, in its reporting on what has been discussed by individuals on business television programs (in particular Business News Network), neither recommends nor promotes any investment strategies.

We paraphrase the experts by hand, we watch the shows and write down what we understood from the experts’ comments. We are human and can make mistakes, help us fix any errors. If you see something that you know is not right or if there is a problem with the site, feel free to email us at : [email protected].

Johnson & Johnson (JNJ)